THE RELEVANCE OF EUROPEAN LEUKEMIA NET RECOMMENDATIONS IN ACUTE MYELOID LEUKEMIA: A ONE CENTER THREE-YEAR EXPERIENCE
Abstract
Aim: The cytogenetic and molecular features of leukemia cells are chief predictors of survival in acute myeloid leukemia (AML). However, treatment outcomes in AML differ between low-, medium and high-income countries. We thus aimed to investigate the relevance of the European Leukemia Net (ELN) prognostic system in Romanian AML patients. Material and methods: We investigated the clinical significance of the ELN recommendations in 130 newly diagnosed AML patients treated at the Iasi Regional Oncology Institute. Results: Favorable, intermediate and adverse risk ELN classes had a similar distribution and retained their prognostic relevance (median overall survival of 18, 11 and 2 months respectively at a median follow-up duration of 18 months) when compared with literature data. However, in both the chemotherapy eligible and ineligible patients a higher prevalence of comorbid conditions and treatment related mortality could be identified. Conclusions: The management of Romanian AML patients poses significant challenges mainly due to higher incidence of comorbid conditions and infections. However, growing access to the allogeneic stem cell transplant procedure in our country will significantly improve the outcome of these patients.
References
2. Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med 2016; 374(23): 2209-2221.
3. Arber DA, Orazi A, Hasserjian R, Borowitz MJ, Beau MM Le, Bloomfield CD, et al. The 2016 revi-sion to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127(20): 2391-2406.
4. Ommen HB. Monitoring minimal residual disease in acute myeloid leukaemia: a review of the current evolving strategies. Ther Adv Hematol 2016; 7(1): 3-16.
5. Deak D, Pop C, Zimta A-A, Jurj A, Ghiaur A, Pasca S, et al. Let’s Talk About BiTEs and Other Drugs in the Real-Life Setting for B-Cell Acute Lymphoblastic Leukemia. Front Immunol 2019; 10: 2856.
6. Larkin K, Blum W. Novel therapies in AML: reason for hope or just hype? Am Soc Clin Oncol Educ Book 2014; e341-51.
7. Szer J. The prevalent predicament of relapsed acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 2012; 2012: 43-48.
8. Burnett AK, Hills RK, Milligan D, Kjeldsen L, Kell J, Russell NH, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol 2011; 29(4): 369-377.
9. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The Importance of Diagnostic Cytogenetics on Outcome in AML: Analysis of 1,612 Patients Entered Into the MRC AML 10 Trial. Blood 1998; 92(7): 2322-2333.
10. Mrózek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood Reviews 2004; 18: 115-136.
11. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and man-agement of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017; 129: 178-189.
12. Deschler B, Lübbert M. Acute myeloid leukemia: Epidemiology and etiology. Cancer 2006; 107(9): 2099-2107.
13. Datoguia TS, Velloso EDRP, Helman R, Musacchio JG, Salvino MA, Soares RA, et al. Overall sur-vival of Brazilian acute myeloid leukemia patients according to the European Leukemia Net prognostic scoring system: a cross-sectional study. Med Oncol 2018; 35: 57-68.
14. Benicio MT de L, Ribeiro AFT, Américo AD, Furtado FM, Glória AB, Lima AS, et al. Evaluation of the European LeukemiaNet recommendations for predicting outcomes of patients with acute myeloid leukemia treated in low- and middle-income countries (LMIC): A Brazilian experience. Leuk Res 2017; 60: 109-114.
15. Vladescu C, Silvia V, Scîntee G, Olsavszky V, Hernández-Quevedo C, Sagan A 18. Romania: Health system review. Vol. 18, Health systems in transition, 2016.
16. Storey S, Gray TF, Bryant AL. Comorbidity, Physical Function, and Quality of Life in Older Adults with Acute Myeloid Leukemia. Curr Geriatr reports 2017; 6(4): 247-254.
17. Van Dongen JJM, Lhermitte L, Böttcher S, Almeida J, Van Der Velden VHJ, Flores-Montero J, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 2012; 26(9): 1908-1975.
18. Röllig C, Bornhäuser M, Thiede C, Taube F, Kramer M, Mohr B, et al. Long-term prognosis of AML according to the new genetic risk classification of the ELN. J Clin Oncol 2011; 29(20): 2758-2765.
19. Pulsoni A, Pagano L, Latagliata R, Casini M, Cerri R, Crugnola M, et al. Survival of elderly patients with acute myeloid leukemia. Haematologica 2004; 89(3): 296-302.
20. Doubek M, Palasek I, Brychtova Y, Buchtova I, Mayer J. Acute myeloid leukemia treatment in patients over 60 years of age. Comparison of symptomatic, palliative, and aggressive therapy. Neoplasma 2005; 52(5): 411-414.
21. Rowe JM, Tallman MS. How I treat acute myeloid leukemia. Blood 2010; 116(17): 3147-3156.
22. Passweg JR, Baldomero H, Basak GW, Chabannon C, Corbacioglu S, Duarte R, et al. The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies. Bone Marrow Transplant 2019; 54(10): 1575-1585.
23. Colita A, Colita A, Bumbea H, Croitoru A, Orban C, Lipan LE, et al. LEAM vs. BEAM vs. CLV Conditioning Regimen for Autologous Stem Cell Transplantation in Malignant Lymphomas. Retro-spective Comparison of Toxicity and Efficacy on 222 Patients in the First 100 Days After Transplant, On Behalf of the Romanian Society for Bone Marrow Transplantation. Front Oncol 2019; 9: 892.
Additional Files
Published
Issue
Section
License
COPYRIGHT
Once an article is accepted for publication, MSJ requests a transfer of copyrights for published articles.
COPYRIGHT TRANSFER FORM FOR
REVISTA MEDICO-CHIRURGICALĂ A SOCIETĂȚII DE MEDICI ȘI NATURALIȘTI DIN IAȘI /
THE MEDICAL-SURGICAL JOURNAL OF THE SOCIETY OF PHYSICIANS AND NATURALISTS FROM IASI
We, the undersigned authors of the manuscript entitled
_____________________________________________________________________________________
_____________________________________________________________________________________
warrant that this manuscript, which is submitted for publication in the REVISTA MEDICO-CHIRURGICALĂ, has not been published and it is not under consideration for publication in another journal.
- we give the consent for publication in the REVISTA MEDICO-CHIRURGICALĂ, in printed and electronic format and we transfer unconditioned and complete the copyright of this manuscript to the REVISTA MEDICO-CHIRURGICALĂ, in the event of its acceptance.
- the manuscript does not break the intellectual property rights of any other person.
- we have read the submitted version of the manuscript and we are fully responsible for the content.
Names and signatures of authors / copyright owners (the following sequence is the authorship of the article):
- ______________________________/_________________________
- ______________________________/_________________________
- ______________________________/_________________________
N.B. All the authors must sign this form
